The DOI matches its OpenAlex record; 1 of the 1 references it cites were found in a registry or an index.
Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model
Open accessAbstract
Psoriasis is a chronic inflammatory disease of the skin characterized by epidermal hyperplasia, dermal angiogenesis, infiltration of activated T cells, and increased cytokine levels. One of these cytokines, IL-15, triggers inflammatory cell recruitment, angiogenesis, and production of other inflammatory cytokines, including IFN-gamma, TNF-alpha, and IL-17, which are all upregulated in psoriatic lesions. To investigate the role of IL-15 in psoriasis, we generated mAb's using human immunoglobulin-transgenic mice. One of the IL-15-specific antibodies we generated, 146B7, did not compete with IL-15 for binding to its receptor but potently interfered with the assembly of the IL-15 receptor alpha, beta, gamma complex. This antibody effectively blocked IL-15-induced T cell proliferation and monocyte TNF-alpha release in vitro. In a human psoriasis xenograft model, antibody 146B7 reduced the severity of psoriasis, as measured by epidermal thickness, grade of parakeratosis, and numbers of inflammatory cells and cycling keratinocytes. These results obtained with this IL-15-specific mAb support an important role for IL-15 in the pathogenesis of psoriasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nickoloff, B. J. (2001) · Journal of Cutaneous Pathology · doi:10.1034/j.1600-0560.2001.280201.x · Cited by 78
Cited by
Pathogenesis and therapy of psoriasis
Lowes, M. A., Bowcock, A. M., & Krueger, J. G. (2007) · Nature · doi:10.1038/nature05663 · Cited by 1,778
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
Waldmann, T. A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1901 · Cited by 1,178
Tesmer, L. A., Lundy, S. K., Sarkar, S., & Fox, D. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00628.x · Cited by 1,102
Psoriasis pathophysiology: current concepts of pathogenesis
Krueger, J. G., & Bowcock, A. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.031120 · Cited by 523
Mechanisms of action of mycophenolate mofetil
Allison, A. (2005) · Lupus · doi:10.1177/096120330501400102 · Cited by 480
Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities
Nickoloff, B. J., & Nestle, F. O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422147 · Cited by 544
“Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis?”
InfluentialHuman antibodies from transgenic animals.
Lonberg, N. (2005) · Nature Biotechnology · doi:10.1038/nbt1135 · Cited by 434
Psoriasiform dermatitis is driven by IL-36–mediated DC-keratinocyte crosstalk
Tortola, L., Rosenwald, E., Abel, B., Blumberg, H., Schäfer, M., Coyle, A. J., Renauld, J.-C., Werner, S., Kisielow, J., & Kopf, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63451 · Cited by 405
IL-15/IL-15 receptor biology: A guided tour through an expanding universe
BUDAGIAN, V, BULANOVA, E., PAUS, R., & BULFONEPAUS, S. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.05.001 · Cited by 385
IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction
Jabri, B., & Abadie, V. (2015) · Nature Reviews Immunology · doi:10.1038/nri3919 · Cited by 315
Immune and inflammatory mechanisms in hypertension
Guzik, T. J., Nosalski, R., Maffia, P., & Drummond, G. R. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00964-1 · Cited by 315
Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo
Richmond, J. M., Strassner, J. P., Zapata, L., Garg, M., Riding, R. L., Refat, M. A., Fan, X., Azzolino, V., Tovar-Garza, A., Tsurushita, N., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7710 · Cited by 301
Ma, F., Plazyo, O., Billi, A. C., Tsoi, L. C., Xing, X., Wasikowski, R., Gharaee-Kermani, M., Hile, G., Jiang, Y., Harms, P. W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39020-4 · Cited by 284
Lew, W., Bowcock, A. M., & Krueger, J. G. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.03.006 · Cited by 284
Ortega, C., Fernández-A, S., Carrillo, J. M., Romero, P., Molina, I. J., Moreno, J. C., & Santamaría, M. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0109046 · Cited by 269
Gudjonsson, J. E., Johnston, A., Dyson, M., Valdimarsson, H., & Elder, J. T. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700807 · Cited by 266
Targeting interleukin‐15 in patients with rheumatoid arthritis: A proof‐of‐concept study
Baslund, B., Tvede, N., Danneskiold‐Samsoe, B., Larsson, P., Panayi, G., Petersen, J., Petersen, L. J., Beurskens, F. J. M., Schuurman, J., van de Winkel, J. G. J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21249 · Cited by 265
Self-citationContribution of Astrocyte-Derived IL-15 to CD8 T Cell Effector Functions in Multiple Sclerosis
Saikali, P., Antel, J. P., Pittet, C. L., Newcombe, J., & Arbour, N. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002188 · Cited by 101
Metadata
- Authors
- Villadsen, L. S., Schuurman, J., Beurskens, F. J. M., Dam, T. N., Dagnæs‐Hansen, F., Skov, L., Rygaard, J., Voorhorst‐Ogink, M. M., Gerritsen, A. F., van Dijk, M. A., Parren, P. W. H. I., Baadsgaard, O., & van de Winkel, J. G. J.
- Venue
- Journal of Clinical Investigation
- Publisher
- American Society for Clinical Investigation
- Published
- 2003-11-14
- Volume
- 112
- Issue
- 10
- Pages
- 1571-1580
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W4233318606
- Cited by
- 192
- References
- 1
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.